The predictive value of CSF multiple assay in multiple sclerosis: A single center experience

被引:16
|
作者
De Fino, C. [1 ]
Lucchini, M. [1 ]
Lucchetti, D. [2 ]
Nociti, V [1 ]
Losavio, F. A. [1 ]
Bianco, A. [1 ]
Colella, F. [2 ]
Ricciardi-Tenore, C. [2 ]
Sgambato, A. [2 ]
Mirabella, M. [1 ]
机构
[1] Univ Cattolica Sacro Cuore, Inst Neurol, Fdn Policlin Univ A Gemelli IRCCS, Largo A Gemelli 8, I-00168 Rome, Italy
[2] Univ Cattolica Sacro Cuore, Inst Gen Pathol, Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy
关键词
Multiple Sclerosis; CHI3L1; sCD163; Osteopontin; BAFF; CHITINASE; 3-LIKE; CEREBROSPINAL-FLUID; OSTEOPONTIN; DISABILITY; BIOMARKER; BAFF;
D O I
10.1016/j.msard.2019.07.030
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Multiple sclerosis (MS) is a chronic, immune-mediated, inflammatory, neurodegenerative disorder. Many studies are investigating the potential role of body fluid biomarkers as prognostic factors for early identification of patients presenting with clinical isolated syndrome (CIS) at high risk for conversion to MS or to recognize RRMS patients at high risk for progression. Objectives: To evaluate the correlation between levels of BAFF, chitinase 3-like 1 (CHI3L1), sCD163, Osteopontin (OPN), both on serum and cerebral spinal fluid (CSF), and the disease activity and progression. We also want to explore a possible relationship between serological and CSF biomarker's levels. Patients and methods: We enrolled 82 patients between June 2014 and June 2016. Seventy-one received a diagnosis of demyelinating disease of CNS (46 RRMS and 25 CIS), while 11 were affected by other neurological diseases. All patients underwent a neural axis MRI, lumbar puncture and blood samples. Levels of BAFF, CHI3L1, sCD163, OPN on serum and CSF were analyzed by Luminex xMAP system, with a kit 11-plex ad hoc. Results: The CSF CHI3L1, sCD163 and OPN levels were significantly higher in MS patients than in controls. We did not find significant differences in serum CHI3L1, sCD163 and OPN levels, nor CSF or serum BAFF levels between patient and control groups. We found significantly higher CSF level of sCD163 and CHI3L1 in all patients' subgroups compared with controls, while OPN was higher in CIS and RR subgroups. We did not find significant differences for serum and CSF levels of all the markers between patients with or without clinical or radiological disease activity. CSF sCD163 and CHI3L1 levels was significant higher in CIS patients who converted to MS (p < 0.05). Using ROC curve analysis, CSF sCD163 resulted the best predictive factor. CSF CHI3L1 and OPN levels resulted useful independent predictors too. Combined ROCS of those three analytes demonstrated a better predictive value, with sCD163 and CHI3L1 resulting as the best combination. Conclusions: CSF sCD163 CHI3L1 and OPN levels were higher in MS patients whereas serum CHI3L1, sCD163 and OPN levels did not show differences compared with controls. This finding confirms the high CSF specificity with regards to the analysis of processes, inflammatory and non-inflammatory, that occur within the CNS.
引用
收藏
页码:176 / 181
页数:6
相关论文
共 50 条
  • [41] intermediate intensity regimen in autologous HSCT for severe Multiple Sclerosis: a a large, single center experience
    Saccardi, R.
    Barilaro, A.
    Fani, A.
    Giannini, M.
    Gozzini, A.
    Guidi, S.
    Innocenti, C.
    Mariottini, A.
    Nozzoli, C.
    Portaccio, E.
    Repice, A. M.
    Amato, M. P.
    Massacesi, L.
    BONE MARROW TRANSPLANTATION, 2016, 51 : S495 - S495
  • [42] Predictive factors for stem cell mobilization failure in multiple myeloma patients: A single center experience
    Goker, Hakan
    Ciftciler, Rafiye
    Demiroglu, Haluk
    Turgut, Mehmet
    Sayinalp, Nilgun
    Haznedaroglu, I. C.
    Okay, Mufide
    Tekin, Fatma
    Buyukasik, Yahya
    TRANSFUSION AND APHERESIS SCIENCE, 2020, 59 (01)
  • [43] Safety and Tolerability of Autologous Hematopoietic Stem Cell Transplant in Multiple Sclerosis: A Single Center Experience
    Singh, Pawan Kumar
    Gambhir, Isha
    Nair, Ragesh Radhakrishnan
    Halder, Rohan
    Shekib, Zahier Ahmad
    Mahajan, Manish
    Singh, Sumit
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 225 - 226
  • [44] Newer disease modifying treatments in pediatric onset multiple sclerosis: Experience from a single center
    Solmaz, Ismail
    Ozen, Pinar Acar
    Parlak, Safak
    Tuncer, Asli
    Anlar, Banu
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2022, 39 : 110 - 115
  • [45] Real world application of ocrelizumab in multiple sclerosis: Single-center experience of 128 patients
    Prockl, Victoria
    Nickel, Florian T.
    Utz, Kathrin S.
    Froehlich, Kilian
    Engelhorn, Tobias
    Hilz, Max-Josef
    Lee, De-Hyung
    Linker, Ralf A.
    Huhn, Konstantin
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2020, 415
  • [46] Multiple Sclerosis in Pregnancy: A single centre multidisciplinary experience
    Onanuga, S.
    Mahmud, M.
    Dhanjal, M.
    Dassan, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 913 - 913
  • [47] Pediatric Multiple Sclerosis-Experience of a Tertiary Care Center
    Martins, Cecilia
    Samoes, Raquel
    Silva, Ana Martins
    Santos, Ernestina
    Figueiroa, Sonia
    NEUROPEDIATRICS, 2023, 54 (01) : 58 - 63
  • [48] Incidence of first multiple sclerosis symptoms during childhood or adolescence: Experience from a regional multiple sclerosis center
    Chitnis, Tanuja
    Gauthier, Susan
    Buckle, Guy
    Glanz, Bonnie
    Khoury, Samia J.
    Weiner, Howard
    NEUROLOGY, 2007, 68 (12) : A161 - A161
  • [49] CSF ANALYSIS IN MULTIPLE-SCLEROSIS
    SINDIC, CJM
    ACTA NEUROLOGICA BELGICA, 1994, 94 (02) : 103 - 111
  • [50] Urinary and CSF biomarkers in multiple sclerosis
    Dobson, R.
    Topping, J.
    Davis, A.
    Giovannoni, G.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 502 - 503